The Survival and Incidence Rate of Ewing Sarcoma; a National Population-based Study in Iran (2008-2015)

Document Type : RESEARCH PAPER


1 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran - Department of Orthopedic Surgery, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2 Department of Biostatics, Faculty of Paramedical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran

3 Department of Orthopedic Surgery, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

4 Cancer Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran

5 Shiraz University of Medical Sciences, Shiraz, Iran


Background: The effect of race and ethnicity on some kind of malignant bone tumors including Ewing sarcoma
has been proven in different studies. In order to evaluate the latter, national cancer registries may help to increase
understanding about potential cancer causes, prevention and control strategies, and apply these findings to control
health problems among populations with similar characteristics.
Methods: A national population-based cancer registry study based on all patients affected by Ewing Sarcoma was
registered in the Iran National Cancer Registry (INCR) between 2008 and 2015 was designed. Demographic data of
microscopically confirmed cases of bone Ewing sarcoma were registered. Patients with Ewing sarcoma were divided
in groups to describe the primary site of the tumor (including axial or appendicular bones) and analyzed. In order to
analyze the survival rate, randomized selection of the patient through the INCR data-base was performed.
Results: A total of 678 cases of malignant Ewing sarcoma of the bone were identified through the INCR. The mean
age of Ewing sarcoma in Iran was 21.53 years. Nearly half of patients were observed at the age group of 15-24. The
total crude incidence rate of Ewing sarcoma was 1.29 in 1 million. The mean 5 year survival rate was 47%. The Mean
survival rate for study population was 5.53.
Conclusion: The crude incidence rate of Ewing sarcoma in Iran is relatively lower with respect to other registries. The
majority of patients are in 15-25 years group and shows affection by Ewing sarcoma in an older age. Socioeconomic
factors had direct influence on survival rate.
Level of evidence: IV


1. Chakraborty D, Rangamani S, Kulothungan V,
Chaturvedi M, Stephen S, Das P,et all. Trends in
incidence of Ewing sarcoma of bone in India–
Evidence from the National Cancer Registry
Programme (1982–2011). Journal of bone oncology.
2. Whelan J, McTiernan A, Cooper N, Wong YK, Francis
M, Vernon S, Strauss SJ. Incidence and survival of
malignant bone sarcomas in England 1979–2007.
International Journal of Cancer. 2012;131(4):
3. Jawad MU, Cheung MC, Min ES, Schneiderbauer MM,
Koniaris LG, Scully SP. Ewing sarcoma demonstrates
racial disparities in incidence‐related and sexrelated
differences in outcome: an analysis of 1631
cases from the SEER database, 1973‐2005. Cancer:
Interdisciplinary International Journal of the
American Cancer Society. 2009;115(15):3526-36.
4. Rica C, Clara V, Island PE. Bone ( C40-41 ) - Both sexes
Percentage distribution of microscopically verified
cases by histological type Bone ( C40-41 ) - Both sexes
( contd ). Bone. X:40–2.
5. Worch J, Matthay KK, Neuhaus J, Goldsby R, DuBois
SG. Ethnic and racial differences in patients
with Ewing sarcoma. Cancer: Interdisciplinary
International Journal of the American Cancer Society.
6. Akbari A, Khayamzadeh M, Salmanian R, Motlagh AG,
Roshandel G, Nouri M, Akbari ME. National Cancer
Mortality-to-Incidence Ratio (MIR) in Iran (2005-
2014). International Journal of Cancer Management.
7. Fritz A, Percy C, Jack A, Shanmugaratnam K, Sobin L,
Parkin D, et al. International Classification of Diseases
for Oncology. 3th edition. Geneva, World Health 
Organization; 2000. Available from: http://whqlibdoc.
8. Movahedi M, Haghighat S, Khayamzadeh M, Moradi
A, Ghanbari-Motlagh A, Mirzaei H, Esmail-Akbari M.
Survival rate of breast cancer based on geographical
variation in Iran, a national study. Iranian Red
Crescent Medical Journal. 2012;14(12):798..
9. Nafissi N, Khayamzadeh M, Zeinali Z, Mohammadi G,
Hosseini M, Akbari ME. Breast Cancer in Iran, from
Epidemiology, Clinicopathological and Biomarker
Feature. Advances in Bioresearch. 2017;8(2).
10. Solooki S, Vosoughi AR, Masoomi V. Epidemiology of
musculoskeletal tumors in Shiraz, south of Iran. Indian
journal of medical and paediatric oncology: official
journal of Indian Society of Medical & Paediatric
Oncology. 2011;32(4):187.
11. Seker MM, Kos T, Ozdemir N, Seker A, Aksoy S, Uncu D,
Zengin N. Treatment and outcomes of Ewing sarcoma
in Turkish adults: a single centre experience. Asian
Pac J Cancer Prev. 2014;15(1):327-30.
12. Bahgat G, Bahgat G. Saudi Arabia. Altern Energy
Middle East. 2013;33(4):78–92.
13. Qureshi A, Ahmad Z, Azam M, Idrees R. Epidemiological
data for common bone sarcomas. Asian Pac J Cancer
Prev. 2010;11(2):393-5.
14. Kutluk MT, Yalçın B, Akyüz C, Varan A, Ruacan Ş,
Büyükpamukçu M. Treatment results and prognostic
factors in Ewing sarcoma. Pediatric hematology and
oncology. 2004;21(7):597-610.
15. Obata H, Ueda T, Kawai A, Ishii T, Ozaki T, Abe S, Tanaka
K, Tsuchiya H, Matsumine A, Yabe H. Clinical outcome
of patients with Ewing sarcoma family of tumors of
bone in Japan: the Japanese Musculoskeletal Oncology
Group cooperative study. Cancer: Interdisciplinary
International Journal of the American Cancer Society.
16. Esiashvili N, Goodman M, Marcus RB. Changes in
incidence and survival of Ewing sarcoma patients over
the past 3 decades: Surveillance Epidemiology and
End Results data. Journal of pediatric hematology/
oncology. 2008;30(6):425-30.